TY - JOUR
T1 - Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab
AU - Coiffier, Bertrand
AU - Li, Weimin
AU - Henitz, Erin D.
AU - Karkera, Jayaprakash D.
AU - Favis, Reyna
AU - Gaffney, Dana
AU - Shapiro, Alice
AU - Theocharous, Panteli
AU - Elsayed, Yusri A.
AU - Van De Velde, Helgi
AU - Schaffer, Michael E.
AU - Osmanov, Evgenii A.
AU - Hong, Xiaonan
AU - Scheliga, Adriana
AU - Mayer, Jiri
AU - Offner, Fritz
AU - Rule, Simon
AU - Teixeira, Adriana
AU - Romejko-Jarosinska, Joanna
AU - De Vos, Sven
AU - Crump, Michael
AU - Shpilberg, Ofer
AU - Zinzani, Pier Luigi
AU - Cakana, Andrew
AU - Esseltine, Dixie Lee
AU - Mulligan, George
AU - Ricci, Deborah
PY - 2013/5/1
Y1 - 2013/5/1
N2 - Purpose: Identify subgroups of patients with relapsed/refractory follicular lymphoma deriving substantial progression-free survival (PFS) benefit with bortezomib-rituximab versus rituximab in the phase III LYM-3001 study. Experimental Design: A total of 676 patients were randomized to five 5-week cycles of bortezomib-rituximab or rituximab. The primary end point was PFS; this prespecified analysis of candidate protein biomarkers and genes was an exploratory objective. Archived tumor tissue and whole blood samples were collected at baseline. Immunohistochemistry and genetic analyses were completed for 4 proteins and 8 genes. Results: In initial pairwise analyses, using individual single-nucleotide polymorphism genotypes, one biomarker pair (PSMB1 P11A C/G heterozygote, low CD68 expression) was associated with a significant PFS benefit with bortezomib-rituximab versus rituximab, controlling for multiple comparison corrections. The pair was analyzed under dominant, recessive, and additive genetic models, with significant association with PFS seen under the dominant model (G/G-C/G). In patients carrying this biomarker pair [PSMB1 P11AGallele, low CD68 expression ( ≤50 CD68-positive cells), population frequency: 43.6%], median PFS was 14.2 months with bortezomib-rituximab versus 9.1 months with rituximab (HR 0.47, P < 0.0001), and there was a significant overall survival benefit (HR 0.49, P = 0.0461). Response rates were higher and time to next antilymphoma therapy was longer in the bortezomib-rituximab group. In biomarker-negative patients, no significant efficacy differences were seen between treatment groups. Similar proportions of patients had high-risk features in the biomarker-positive and biomarker-negative subsets. Conclusions: Patients with PSMB1 P11A (G allele) and low CD68 expression seemed to have significantly longer PFS and greater clinical benefit with bortezomib-rituximab versus rituximab.
AB - Purpose: Identify subgroups of patients with relapsed/refractory follicular lymphoma deriving substantial progression-free survival (PFS) benefit with bortezomib-rituximab versus rituximab in the phase III LYM-3001 study. Experimental Design: A total of 676 patients were randomized to five 5-week cycles of bortezomib-rituximab or rituximab. The primary end point was PFS; this prespecified analysis of candidate protein biomarkers and genes was an exploratory objective. Archived tumor tissue and whole blood samples were collected at baseline. Immunohistochemistry and genetic analyses were completed for 4 proteins and 8 genes. Results: In initial pairwise analyses, using individual single-nucleotide polymorphism genotypes, one biomarker pair (PSMB1 P11A C/G heterozygote, low CD68 expression) was associated with a significant PFS benefit with bortezomib-rituximab versus rituximab, controlling for multiple comparison corrections. The pair was analyzed under dominant, recessive, and additive genetic models, with significant association with PFS seen under the dominant model (G/G-C/G). In patients carrying this biomarker pair [PSMB1 P11AGallele, low CD68 expression ( ≤50 CD68-positive cells), population frequency: 43.6%], median PFS was 14.2 months with bortezomib-rituximab versus 9.1 months with rituximab (HR 0.47, P < 0.0001), and there was a significant overall survival benefit (HR 0.49, P = 0.0461). Response rates were higher and time to next antilymphoma therapy was longer in the bortezomib-rituximab group. In biomarker-negative patients, no significant efficacy differences were seen between treatment groups. Similar proportions of patients had high-risk features in the biomarker-positive and biomarker-negative subsets. Conclusions: Patients with PSMB1 P11A (G allele) and low CD68 expression seemed to have significantly longer PFS and greater clinical benefit with bortezomib-rituximab versus rituximab.
UR - http://www.scopus.com/inward/record.url?scp=84877088158&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-12-3069
DO - 10.1158/1078-0432.CCR-12-3069
M3 - Article
C2 - 23549871
AN - SCOPUS:84877088158
SN - 1078-0432
VL - 19
SP - 2551
EP - 2561
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 9
ER -
